In the last few years, the availability of next-generation sequencing (NGS) has enabled screening for a number of genes on patients with suspected HDGC lacking CDH1 pathogenic variants. The gene discussed is CDH1; the disease is CDH1-related diffuse gastric and lobular breast cancer syndrome.